Literature DB >> 22825217

Kinesins and cancer.

Oliver Rath1, Frank Kozielski.   

Abstract

Kinesins are a family of molecular motors that travel unidirectionally along microtubule tracks to fulfil their many roles in intracellular transport or cell division. Over the past few years kinesins that are involved in mitosis have emerged as potential targets for cancer drug development. Several compounds that inhibit two mitotic kinesins (EG5 (also known as KIF11) and centromere-associated protein E (CENPE)) have entered Phase I and II clinical trials either as monotherapies or in combination with other drugs. Additional mitotic kinesins are currently being validated as drug targets, raising the possibility that the range of kinesin-based drug targets may expand in the future.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22825217     DOI: 10.1038/nrc3310

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  205 in total

Review 1.  Stirring up development with the heterotrimeric kinesin KIF3.

Authors:  N Hirokawa
Journal:  Traffic       Date:  2000-01       Impact factor: 6.215

Review 2.  Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale.

Authors:  Edina Komlodi-Pasztor; Dan L Sackett; Antonio Tito Fojo
Journal:  Clin Cancer Res       Date:  2012-01-01       Impact factor: 12.531

3.  Effects of anti-microtubule agents on microtubule organization in cells lacking the kinesin-13 MCAK.

Authors:  David G Hedrick; Jane R Stout; Claire E Walczak
Journal:  Cell Cycle       Date:  2008-05-07       Impact factor: 4.534

4.  Kinesin-12, a mitotic microtubule-associated motor protein, impacts axonal growth, navigation, and branching.

Authors:  Mei Liu; Vidya C Nadar; Frank Kozielski; Marta Kozlowska; Wenqian Yu; Peter W Baas
Journal:  J Neurosci       Date:  2010-11-03       Impact factor: 6.167

5.  ATP hydrolysis in Eg5 kinesin involves a catalytic two-water mechanism.

Authors:  Courtney L Parke; Edward J Wojcik; Sunyoung Kim; David K Worthylake
Journal:  J Biol Chem       Date:  2009-12-15       Impact factor: 5.157

6.  Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes.

Authors:  Gopeshwar Narayan; Veronique Bourdon; Seeta Chaganti; Hugo Arias-Pulido; Subhadra V Nandula; Pulivarthi H Rao; Lutz Gissmann; Matthias Dürst; Achim Schneider; Bhavana Pothuri; Mahesh Mansukhani; Katia Basso; R S K Chaganti; Vundavalli V Murty
Journal:  Genes Chromosomes Cancer       Date:  2007-04       Impact factor: 5.006

7.  Upregulation of Rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma.

Authors:  Suk Mei Wang; London Lucien P J Ooi; Kam M Hui
Journal:  Clin Cancer Res       Date:  2011-08-08       Impact factor: 12.531

8.  The human kinesin Kif18A is a motile microtubule depolymerase essential for chromosome congression.

Authors:  Monika I Mayr; Stefan Hümmer; Jenny Bormann; Tamara Grüner; Sarah Adio; Guenther Woehlke; Thomas U Mayer
Journal:  Curr Biol       Date:  2007-03-08       Impact factor: 10.834

9.  Beta-arrestin-mediated localization of smoothened to the primary cilium.

Authors:  Jeffrey J Kovacs; Erin J Whalen; Renshui Liu; Kunhong Xiao; Jihee Kim; Minyong Chen; Jiangbo Wang; Wei Chen; Robert J Lefkowitz
Journal:  Science       Date:  2008-05-22       Impact factor: 47.728

10.  Phosphorylation of mitotic kinesin-like protein 2 by polo-like kinase 1 is required for cytokinesis.

Authors:  Rüdiger Neef; Christian Preisinger; Josephine Sutcliffe; Robert Kopajtich; Erich A Nigg; Thomas U Mayer; Francis A Barr
Journal:  J Cell Biol       Date:  2003-08-25       Impact factor: 10.539

View more
  185 in total

1.  Centromere-associated protein E expresses a novel mRNA isoform in acute lymphoblastic leukemia.

Authors:  Cindy E Jiménez-Ávila; Vanessa Villegas-Ruíz; Marta Zapata-Tarres; Alejandra E Rubio-Portillo; Eleazar I Pérez López; Juan C Zenteno; Sergio Juárez-Méndez
Journal:  Int J Mol Epidemiol Genet       Date:  2018-10-20

2.  Structure-Guided Design of Novel l-Cysteine Derivatives as Potent KSP Inhibitors.

Authors:  Naohisa Ogo; Yoshinobu Ishikawa; Jun-Ichi Sawada; Kenji Matsuno; Akihiro Hashimoto; Akira Asai
Journal:  ACS Med Chem Lett       Date:  2015-07-22       Impact factor: 4.345

3.  The structural kinetics of switch-1 and the neck linker explain the functions of kinesin-1 and Eg5.

Authors:  Joseph M Muretta; Yonggun Jun; Steven P Gross; Jennifer Major; David D Thomas; Steven S Rosenfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-16       Impact factor: 11.205

Review 4.  Mitosis as an anti-cancer drug target.

Authors:  Anna-Leena Salmela; Marko J Kallio
Journal:  Chromosoma       Date:  2013-06-18       Impact factor: 4.316

Review 5.  Targeting mitotic pathways for endocrine-related cancer therapeutics.

Authors:  Shivangi Agarwal; Dileep Varma
Journal:  Endocr Relat Cancer       Date:  2017-06-14       Impact factor: 5.678

6.  A TOP2A-derived cancer panel drives cancer progression in papillary renal cell carcinoma.

Authors:  Mushi Ye; Zhuobin He; Wei Dai; Zhuo Li; Xiaojun Chen; Jianjun Liu
Journal:  Oncol Lett       Date:  2018-07-19       Impact factor: 2.967

7.  Synergism between inhibitors of Aurora A and KIF11 overcomes KIF15-dependent drug resistance.

Authors:  Hoi Tang Ma; Sergio Erdal; Shan Huang; Randy Y C Poon
Journal:  Mol Oncol       Date:  2014-06-02       Impact factor: 6.603

8.  The microarray gene profiling analysis of glioblastoma cancer cells reveals genes affected by FAK inhibitor Y15 and combination of Y15 and temozolomide.

Authors:  Grace Huang; Baotran Ho; Jeffrey Conroy; Song Liu; Hu Qiang; Vita Golubovskaya
Journal:  Anticancer Agents Med Chem       Date:  2014-01       Impact factor: 2.505

Review 9.  Clinically Applicable Inhibitors Impacting Genome Stability.

Authors:  Anu Prakash; Juan F Garcia-Moreno; James A L Brown; Emer Bourke
Journal:  Molecules       Date:  2018-05-13       Impact factor: 4.411

10.  Eg5 inhibitor, a novel potent targeted therapy, induces cell apoptosis in renal cell carcinoma.

Authors:  Sentai Ding; Zuohui Zhao; Dingqi Sun; Fei Wu; Dongbin Bi; Jiaju Lu; Naidong Xing; Liang Sun; Haihu Wu; Kejia Ding
Journal:  Tumour Biol       Date:  2014-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.